Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer

A case-based review

Alex Adjei, George Blumenschein, Sumithra J Mandrekar, Shauna Hillman, Ulrich Gatzemeier, David Heigener

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Sorafenib, a small-molecule inhibitor of multiple kinases involved in tumor growth and progression, is approved for the treatment of advanced renal-cell carcinoma and advanced hepatocellular carcinoma. Encouraging activity and good tolerability of daily oral sorafenib, either as a single agent or in combination with gefitinib, have been demonstrated in phase I-II trials in patients with advanced non-small-cell lung cancer (NSCLC). Currently, minimal data are available describing the long-term safety and tolerability of sorafenib in patients with NSCLC. Materials and Methods: We describe a series of 12 patients with advanced NSCLC (derived from 1 phase I and 2 phase II trials) who achieved long-term (ie, > 12 months) disease control and continued to receive sorafenib alone or in combination with gefitinib beyond the end of the study in which they were enrolled. Results: The safety profile of sorafenib administered on a long-term basis did not differ significantly from that seen previously in the shorter term. The majority of adverse events (AEs) were Grade 1-2 in severity. Five of the 12 patients experienced no ≥ Grade 3 AEs. There was no evidence of increased frequency or severity of AEs over time, or of late AEs, and no patient in this series discontinued study treatment because of AEs. Conclusion: In patients with advanced NSCLC who achieve a prolonged response or stable disease with sorafenib given as a single agent or as part of a combination regimen, sorafenib treatment could be continued until disease progression without major long-term safety or tolerability problems.

Original languageEnglish (US)
Pages (from-to)212-217
Number of pages6
JournalClinical Lung Cancer
Volume12
Issue number4
DOIs
StatePublished - Jul 1 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Safety
sorafenib
Renal Cell Carcinoma
Disease Progression
Hepatocellular Carcinoma
Phosphotransferases
Therapeutics
Growth
Neoplasms

Keywords

  • Anti-angiognesis
  • Epidermal growth factor receptor
  • Gefitinib
  • Multikinase inhibitor
  • Toxicity
  • Tyrosine kinase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer : A case-based review. / Adjei, Alex; Blumenschein, George; Mandrekar, Sumithra J; Hillman, Shauna; Gatzemeier, Ulrich; Heigener, David.

In: Clinical Lung Cancer, Vol. 12, No. 4, 01.07.2011, p. 212-217.

Research output: Contribution to journalArticle

Adjei, Alex ; Blumenschein, George ; Mandrekar, Sumithra J ; Hillman, Shauna ; Gatzemeier, Ulrich ; Heigener, David. / Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer : A case-based review. In: Clinical Lung Cancer. 2011 ; Vol. 12, No. 4. pp. 212-217.
@article{8f4f224be6b947ccbb9f60bd1dbae308,
title = "Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: A case-based review",
abstract = "Background: Sorafenib, a small-molecule inhibitor of multiple kinases involved in tumor growth and progression, is approved for the treatment of advanced renal-cell carcinoma and advanced hepatocellular carcinoma. Encouraging activity and good tolerability of daily oral sorafenib, either as a single agent or in combination with gefitinib, have been demonstrated in phase I-II trials in patients with advanced non-small-cell lung cancer (NSCLC). Currently, minimal data are available describing the long-term safety and tolerability of sorafenib in patients with NSCLC. Materials and Methods: We describe a series of 12 patients with advanced NSCLC (derived from 1 phase I and 2 phase II trials) who achieved long-term (ie, > 12 months) disease control and continued to receive sorafenib alone or in combination with gefitinib beyond the end of the study in which they were enrolled. Results: The safety profile of sorafenib administered on a long-term basis did not differ significantly from that seen previously in the shorter term. The majority of adverse events (AEs) were Grade 1-2 in severity. Five of the 12 patients experienced no ≥ Grade 3 AEs. There was no evidence of increased frequency or severity of AEs over time, or of late AEs, and no patient in this series discontinued study treatment because of AEs. Conclusion: In patients with advanced NSCLC who achieve a prolonged response or stable disease with sorafenib given as a single agent or as part of a combination regimen, sorafenib treatment could be continued until disease progression without major long-term safety or tolerability problems.",
keywords = "Anti-angiognesis, Epidermal growth factor receptor, Gefitinib, Multikinase inhibitor, Toxicity, Tyrosine kinase",
author = "Alex Adjei and George Blumenschein and Mandrekar, {Sumithra J} and Shauna Hillman and Ulrich Gatzemeier and David Heigener",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.cllc.2011.03.021",
language = "English (US)",
volume = "12",
pages = "212--217",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer

T2 - A case-based review

AU - Adjei, Alex

AU - Blumenschein, George

AU - Mandrekar, Sumithra J

AU - Hillman, Shauna

AU - Gatzemeier, Ulrich

AU - Heigener, David

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background: Sorafenib, a small-molecule inhibitor of multiple kinases involved in tumor growth and progression, is approved for the treatment of advanced renal-cell carcinoma and advanced hepatocellular carcinoma. Encouraging activity and good tolerability of daily oral sorafenib, either as a single agent or in combination with gefitinib, have been demonstrated in phase I-II trials in patients with advanced non-small-cell lung cancer (NSCLC). Currently, minimal data are available describing the long-term safety and tolerability of sorafenib in patients with NSCLC. Materials and Methods: We describe a series of 12 patients with advanced NSCLC (derived from 1 phase I and 2 phase II trials) who achieved long-term (ie, > 12 months) disease control and continued to receive sorafenib alone or in combination with gefitinib beyond the end of the study in which they were enrolled. Results: The safety profile of sorafenib administered on a long-term basis did not differ significantly from that seen previously in the shorter term. The majority of adverse events (AEs) were Grade 1-2 in severity. Five of the 12 patients experienced no ≥ Grade 3 AEs. There was no evidence of increased frequency or severity of AEs over time, or of late AEs, and no patient in this series discontinued study treatment because of AEs. Conclusion: In patients with advanced NSCLC who achieve a prolonged response or stable disease with sorafenib given as a single agent or as part of a combination regimen, sorafenib treatment could be continued until disease progression without major long-term safety or tolerability problems.

AB - Background: Sorafenib, a small-molecule inhibitor of multiple kinases involved in tumor growth and progression, is approved for the treatment of advanced renal-cell carcinoma and advanced hepatocellular carcinoma. Encouraging activity and good tolerability of daily oral sorafenib, either as a single agent or in combination with gefitinib, have been demonstrated in phase I-II trials in patients with advanced non-small-cell lung cancer (NSCLC). Currently, minimal data are available describing the long-term safety and tolerability of sorafenib in patients with NSCLC. Materials and Methods: We describe a series of 12 patients with advanced NSCLC (derived from 1 phase I and 2 phase II trials) who achieved long-term (ie, > 12 months) disease control and continued to receive sorafenib alone or in combination with gefitinib beyond the end of the study in which they were enrolled. Results: The safety profile of sorafenib administered on a long-term basis did not differ significantly from that seen previously in the shorter term. The majority of adverse events (AEs) were Grade 1-2 in severity. Five of the 12 patients experienced no ≥ Grade 3 AEs. There was no evidence of increased frequency or severity of AEs over time, or of late AEs, and no patient in this series discontinued study treatment because of AEs. Conclusion: In patients with advanced NSCLC who achieve a prolonged response or stable disease with sorafenib given as a single agent or as part of a combination regimen, sorafenib treatment could be continued until disease progression without major long-term safety or tolerability problems.

KW - Anti-angiognesis

KW - Epidermal growth factor receptor

KW - Gefitinib

KW - Multikinase inhibitor

KW - Toxicity

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=79960343099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960343099&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2011.03.021

DO - 10.1016/j.cllc.2011.03.021

M3 - Article

VL - 12

SP - 212

EP - 217

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 4

ER -